Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

被引：3
|
作者：
Kim, S-B. [1 ]
Keam, B. [2 ]
Shin, S. [3 ]
Chae, Y. S. [4 ]
Seo, S. [1 ]
Park, K. [5 ]
Kim, T. M. [2 ]
Park, L. C. [3 ]
Hong, S-B. [6 ]
Lim, E. [7 ]
Lee, S. [7 ]
Ahn, M-J. [5 ]
机构：
[1] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[3] Kosin Univ Gospel Hosp, Dept Oncol Internal Med, Busan, South Korea
[4] Kyungpook Natl Univ, Chilgok Hosp, Dept Hematol Oncol, Daegu, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Dept Med, Seoul, South Korea
[6] ISU Abxis Co Ltd, Drug Dev, Seongnam, South Korea
[7] ISU Abxis Co Ltd, Clin Trial Team, Seongnam, South Korea
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
928P
引用
收藏
页码：S667 / S668
页数：2
相关论文
共 50 条
  • [1] Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Kim, S-B.
    Keam, B.
    Shin, S-H.
    Chae, Y.
    Seo, S.
    Park, K.
    Kim, T. M.
    Park, L. C.
    Hong, S-B.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2021, 32 : S797 - S797
  • [2] A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer
    Seo, Seyoung
    Keam, Bhumsuk
    Shin, Seong Hoon
    Chae, Yee Soo
    Kim, Tae Min
    Park, Lee Chun
    Hong, Seung-Beom
    Ahn, Myung-Ju
    Kim, Sung-Bae
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (08) : 1501 - 1511
  • [3] Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Duwuri, Umamaheswar
    Ferris, Robert L.
    Ohr, James
    Gooding, William E.
    Kim, Seungwon
    Johnson, Jonas Talmadge
    Grandis, Jennifer R.
    Stabile, Laura P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Bauman, J. E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study
    Chung, Christine
    Bonomi, Marcelo
    Steuer, Conor
    Schell, Michael
    Li, Jiannong
    Johnson, Matthew
    McMullen, Caitlin
    Wadsworth, J. Trad
    Patel, Krupal
    Kish, Julie
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James
    Saba, Nabil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [7] Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Geiger, J. L.
    Egloff, A. M.
    Ohr, J.
    Stabile, L.
    Gooding, W.
    Flaherty, J.
    Gibson, M.
    Grandis, J.
    Bauman, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 930 - 930
  • [8] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Considine, Michael
    Fekrazad, M. Houman
    Howard, Jason
    Bishop, Justin A.
    Olson, Garth T.
    Jones, Dennie V.
    Fertig, Elana J.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Ji, D.
    Sang, Y.
    Liu, X.
    Guo, Y.
    Yang, Y.
    Chen, G.
    Dong, S.
    Wang, Y.
    He, X.
    Ying, H.
    Lu, X.
    Wang, Y.
    Hu, C.
    Ji, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S626 - S626
  • [10] Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Garralda, E.
    Villacampa Javierre, G.
    Feliu, B.
    Martinez, S.
    Gutierrez, R.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - 59
12345